AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37310781 — intervention group
Group type: COMPARATOR
Intervention: Digital training (DT) course with weekly individualized coaching
Number of subjects: 262
Study 37310790 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 22
Study 37310790 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 22
Study 37310872 — intervention group
Group type: COMPARATOR
Intervention: Dantu heterozygotes
Number of subjects: 141
Study 37310872 — intervention group
Group type: COMPARATOR
Intervention: Dantu homozygotes
Number of subjects: 141
Study 37310872 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Dantu subjects
Number of subjects: 141
Study 37310877 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased adalimumab dose intervals
Number of subjects: 174
Study 37310877 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing interval
Number of subjects: 174
Study 37310983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile technology interventions (iBreast Exam device, mobile breast ultrasound, mobile mammography) and patient navigation
Number of subjects: 0
Study 37310983 — intervention group
Group type: COMPARATOR
Intervention: Breast cancer awareness education (Control group)
Number of subjects: 0
Study 37311055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Temsirolimus, and Valproic Acid
Number of subjects: 47
Study 37311111 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused skills training
Number of subjects: 0
Study 37311111 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37311173 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 13
Study 37311202 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37311248 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxia exposure
Number of subjects: 0
Study 37311429 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Number of subjects: 0
Study 37311468 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (1.0 mg/kg body weight subcutaneously every 3 weeks, titrated up to 1.75 mg/kg)
Number of subjects: 356
Study 37311468 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (450 IU/kg body weight subcutaneously once a week, titrated up to 1050 IU/kg)
Number of subjects: 356
Study 37311694 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-coated patch
Number of subjects: 227
Study 37311694 — intervention group
Group type: COMPARATOR
Intervention: Drainage
Number of subjects: 227
Study 37311720 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural lifestyle interventions (dietary changes, physical activity, moderate weight loss)
Number of subjects: 685
Study 37311722 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron (200 mg BID)
Number of subjects: 151
Study 37311722 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron (low [5-mg] or high [10-mg] starting dose, escalating to 80, 120 or 200 mg BID)
Number of subjects: 151
Study 37311722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 37311823 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA
Number of subjects: 1127
Study 37311823 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CHA
Number of subjects: 1127
Study 37311823 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up CHA
Number of subjects: 1127
Study 37311823 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta CHA
Number of subjects: 1127
Study 37312017 — intervention group
Group type: EXPERIMENTAL
Intervention: High women's empowerment
Number of subjects: 1609
Study 37312017 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment-based interventions targeting women's decision-making and control over assets
Number of subjects: 1609
Study 37312021 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium patients
Number of subjects: 76
Study 37312021 — intervention group
Group type: COMPARATOR
Intervention: Non-delirium patients
Number of subjects: 76
Study 37312021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 37312053 — intervention group
Group type: EXPERIMENTAL
Intervention: HYDRA proton- and photon radiotherapy (40 Gy elective dose, 55 Gy simultaneous integrated boost, 59 Gy focal boost)
Number of subjects: 100
Study 37312053 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (not specified)
Number of subjects: 100
Study 37312054 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of anti-PD-1 immunotherapy with avelumab
Number of subjects: 58
Study 37312054 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly detailed in the abstract)
Number of subjects: 58
Study 37312079 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Human Avatars (DHA) using multi-omics data and clinical factors
Number of subjects: 600
Study 37312086 — intervention group
Group type: EXPERIMENTAL
Intervention: non-standard targeted therapy based on potentially actionable molecular alterations or biomarkers
Number of subjects: 500
Study 37312095 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactoglobulin supplementation with resistance exercise training
Number of subjects: 24
Study 37312095 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (dextrose) control with resistance exercise training
Number of subjects: 24
Study 37312104 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient computed tomography coronary angiography (CTCA) plus standard of care
Number of subjects: 2270
Study 37312104 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 2270
Study 37312118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative team combined with palliative care model
Number of subjects: 84
Study 37312118 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing intervention
Number of subjects: 84
Study 37312127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano X CBCT scans
Number of subjects: 30
Study 37312127 — intervention group
Group type: COMPARATOR
Intervention: Conventional CBCT scans
Number of subjects: 30
Study 37312140 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhineng Qigong intervention (12-week training with face-to-face group activities and individual training)
Number of subjects: 52
Study 37312165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Number of subjects: 0
Study 37312165 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of neoadjuvant CAPOX (oxaliplatin 130 mg/m2)
Number of subjects: 0
Study 37312222 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Pathway Pharmacist intervention
Number of subjects: 108
Study 37312222 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 108
Study 37312233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks)
Number of subjects: 136
Study 37312233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 37312251 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37312287 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flow regulator (AFR) implantation
Number of subjects: 87
Study 37312287 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flow regulator (AFR) implantation in HFpEF patients
Number of subjects: 87
Study 37312287 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flow regulator (AFR) implantation in HFrEF patients
Number of subjects: 87
Study 37312287 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-related deaths in HFrEF subgroup
Number of subjects: 87
Study 37312582 — intervention group
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) intervention
Number of subjects: 0
Study 37312666 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural counselling intervention to increase moderate-to-vigorous-intensity physical activity (MVPA) and decrease sedentary-time (SED-time)
Number of subjects: 300
Study 37312666 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 37313367 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma (ACQ-5 score > 1.5)
Number of subjects: 109
Study 37313367 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of anxiety (HADS-A score > 7)
Number of subjects: 109
Study 37313367 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression (HADS-D score > 7)
Number of subjects: 109
Study 37313367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HADS-A score
Number of subjects: 109
Study 37313367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HADS-D score
Number of subjects: 109
Study 37313403 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus chemotherapy (TC)
Number of subjects: 0
Study 37313403 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (PC)
Number of subjects: 0
Study 37313851 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium oxide ingestion before and after rupture
Number of subjects: 18
Study 37313851 — intervention group
Group type: COMPARATOR
Intervention: Control samples (not specified)
Number of subjects: 18
Study 37313946 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 86
Study 37314061 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal lampalizumab (monthly)
Number of subjects: 4052
Study 37314061 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal lampalizumab (every-other-month)
Number of subjects: 4052
Study 37314061 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal pegcetacoplan (monthly)
Number of subjects: 4052
Study 37314061 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal pegcetacoplan (every-other-month)
Number of subjects: 4052
Study 37314061 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal avacincaptad pegol (monthly, 2 mg)
Number of subjects: 4052
Study 37314061 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal avacincaptad pegol (monthly, 4 mg)
Number of subjects: 4052
Study 37314165 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab (specific dabigatran reversal agent)
Number of subjects: 0
Study 37314165 — intervention group
Group type: COMPARATOR
Intervention: Andexanet alfa (for Xa inhibitors apixaban and rivaroxaban)
Number of subjects: 0
Study 37314165 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 0
Study 37314165 — intervention group
Group type: COMPARATOR
Intervention: Standard approaches for managing DOAC-treated patients requiring emergency surgery
Number of subjects: 0
Study 37314197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 10 (BMP10) plasma concentrations
Number of subjects: 1112
Study 37314197 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed BMP10 concentration
Number of subjects: 1112
Study 37314197 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed BMP10 concentration after multivariable adjustment
Number of subjects: 1112
Study 37314197 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP10 quartiles
Number of subjects: 1112
Study 37314235 — intervention group
Group type: EXPERIMENTAL
Intervention: Population health care (usual care plus assessment via portal)
Number of subjects: 175
Study 37314235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (assessment during triage at visits)
Number of subjects: 175
Study 37314244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before hospital admission, followed by 1 g infusion over 8 hours)
Number of subjects: 1310
Study 37314244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1310
Study 37314244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1310
Study 37314275 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 452
Study 37314275 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 452
Study 37314323 — intervention group
Group type: EXPERIMENTAL
Intervention: tUEFMA (remote version of UEFMA)
Number of subjects: 22
Study 37314323 — intervention group
Group type: EXPERIMENTAL
Intervention: tUEFMA
Number of subjects: 22
Study 37314435 — intervention group
Group type: EXPERIMENTAL
Intervention: New paediatric VO2max Z-score reference equations
Number of subjects: 344
Study 37314435 — intervention group
Group type: COMPARATOR
Intervention: Cooper's weight- and height-based linear equations
Number of subjects: 344
Study 37314501 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 160 mg daily with trametinib 1 mg, 5 days on and 2 days off
Number of subjects: 20
Study 37314501 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 160 mg daily with trametinib 1 mg daily (DL1)
Number of subjects: 20
Study 37314501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis
Number of subjects: 20
Study 37314530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ketone tracer (R)-[1-
Number of subjects: 0
Study 37314530 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ketone tracer (R)-[1-
Number of subjects: 0
Study 37314665 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept 125 mg once weekly
Number of subjects: 0
Study 37314797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic (8 billion colony-forming units per day) for 8 weeks
Number of subjects: 50
Study 37314797 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 50
Study 37314839 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs) including goal-setting, self-monitoring, feedback, and action planning, each delivered for 2 weeks over a total of 10 weeks.
Number of subjects: 60
Study 37314844 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 200
Study 37314844 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions (FGDs) with adolescents and youths living with HIV
Number of subjects: 200
Study 37314844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional survey
Number of subjects: 200
Study 37314844 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial
Number of subjects: 200
Study 37314845 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior Reduction in Pregnancy Intervention (SPRING)
Number of subjects: 53
Study 37314845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study 37314850 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Circuit (adaptive case management approach)
Number of subjects: 204
Study 37315062 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Number of subjects: 61
Study 37315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intolerance-of-uncertainty therapy (IUT)
Number of subjects: 64
Study 37315099 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 64
Study 37315099 — intervention group
Group type: COMPARATOR
Intervention: Both IUT and MCT
Number of subjects: 64
Study 37315114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 46
Study 37315119 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 52911
Study 37315119 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 52911
Study 37315225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 0
Study 37315225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 37315225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37315225 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment
Number of subjects: 0
Study 37315261 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 8
Study 37315265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T)
Number of subjects: 28
Study 37315268 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd)
Number of subjects: 103
Study 37315268 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide, or lenalidomide, dexamethasone, and cyclophosphamide (MyeXI treatment)
Number of subjects: 103
Study 37315297 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO (EBRT + BT)
Number of subjects: 579
Study 37315297 — intervention group
Group type: COMPARATOR
Intervention: BT alone
Number of subjects: 579
Study 37315325 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPTURE intervention
Number of subjects: 0
Study 37315558 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intramuscular GRAd-COV2 administration
Number of subjects: 917
Study 37315558 — intervention group
Group type: EXPERIMENTAL
Intervention: Second administration of GRAd-COV2
Number of subjects: 917
Study 37315558 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Number of subjects: 917
Study 37315558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 917
Study 37315558 — intervention group
Group type: EXPERIMENTAL
Intervention: Two vaccine injections
Number of subjects: 917
Study 37315558 — intervention group
Group type: COMPARATOR
Intervention: Two doses of placebo
Number of subjects: 917
Study 37315579 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-506 with single dose irradiation
Number of subjects: 2
Study 37315579 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-506 with fractionated irradiation
Number of subjects: 2
Study 37315579 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-506
Number of subjects: 2
Study 37315579 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2
Study 37315583 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab combined with MMC-5FU-based chemoradiotherapy (CRT)
Number of subjects: 45
Study 37315583 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab combined with MMC-5FU-based CRT
Number of subjects: 45
Study 37315590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (initiated at 5 mg/day, up-titrated to 10 mg/day at day 8, flexible dosing thereafter [5-20 mg/day])
Number of subjects: 82
Study 37315590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 82
Study 37315794 — intervention group
Group type: EXPERIMENTAL
Intervention: High light physical activity (≥760 counts/min)
Number of subjects: 50
Study 37315794 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activity (0-100 counts/min), low light activity (101-759 counts/min), moderate and vigorous activity (≥1952 counts/min)
Number of subjects: 50
Study 37315879 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) cMRI
Number of subjects: 67
Study 37315879 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic measurements
Number of subjects: 67
Study 37315879 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentrations of NT-proBNP
Number of subjects: 67
Study 37315924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of DHA-rich fish oil (1.1 g/d DHA and 0.4 g/d EPA) and cocoa flavanols (500 mg/d flavan-3-ols)
Number of subjects: 259
Study 37315924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of DHA-rich fish oil and cocoa flavanols
Number of subjects: 259
Study 37315924 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 259
Study 37316145 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA unblinded group
Number of subjects: 219
Study 37316145 — intervention group
Group type: COMPARATOR
Intervention: CCTA blinded group
Number of subjects: 219
Study 37316162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low LVEF (<55%)
Number of subjects: 734
Study 37316162 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal LVEF (55%-65%)
Number of subjects: 734
Study 37316162 — intervention group
Group type: COMPARATOR
Intervention: High LVEF (>65%)
Number of subjects: 734
Study 37316163 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 50
Study 37316311 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide as an adjunct to nicotine patches
Number of subjects: 216
Study 37316311 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 216
Study 37316315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser (LLL) with glass ionomer sealant and fluoride toothpaste
Number of subjects: 50
Study 37316315 — intervention group
Group type: COMPARATOR
Intervention: Sham low-level laser (LLL) with glass ionomer sealant and fluoride toothpaste
Number of subjects: 50
Study 37316316 — intervention group
Group type: COMPARATOR
Intervention: Control participants (n=427)
Number of subjects: 609
Study 37316316 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (n=182)
Number of subjects: 609
Study 37316316 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study recruitment
Number of subjects: 609
Study 37316318 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified mobile health application (iGAME) for 12 weeks
Number of subjects: 0
Study 37316318 — intervention group
Group type: COMPARATOR
Intervention: Education about the benefits of physical activity (Control)
Number of subjects: 0
Study 37316690 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 4183
Study 37316690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4183
Study 37316692 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg orally once daily
Number of subjects: 1350
Study 37316728 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd)
Number of subjects: 73
Study 37316784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine alone
Number of subjects: 0
Study 37316784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine + oxaliplatin
Number of subjects: 0